March 04, 2010 05:50 PM Eastern Daylight Time
BUSINESS WIRE

CSL Behring Receives FDA Approval of HizentraTM, First 20 Percent Subcutaneous Immunoglobulin Therapy

New high concentration, at-home therapy offers convenience to patients managing primary immunodeficiency (Photo: Business Wire)
New high concentration, at-home therapy offers convenience to patients managing primary immunodeficiency (Photo: Business Wire)
View Full Size Opens in new window

Download